Your Position:Home>Products>Monoclonals/Polyclonals>Anti-Human CRACC/SLAMF7 Reference Antibody

Anti-Human CRACC/SLAMF7 Reference Antibody

  • Cat. No.:RB9THV217026
  • Price:Negotiable
  • Clicks:358

Product Detail

Product Parameters

FormLiquid
Host SpeciesHumanized
ClonalityMonoclonal
IsotypeIgG1-kappa
Purity>95% purity as determined by SDS-PAGE.
PurificationProtein A/G purified from cell culture supernatant.
Concentration1mg/ml
Endotoxin LevelPlease contact the lab for this information.
ApplicationsELISA, Bioactivity: FACS, Functional assay, Research in vivo
Species ReactivityHuman
TargetSLAMF7, CRACC, Protein 19A, SLAM family member 7, CD2-like receptor-activating cytotoxic cells, Membrane protein FOAP-12, CD319, Novel Ly9, CD2 subset 1, CS1
Storage Buffer0.01M PBS, pH 7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Expression SystemMammalian Cells
Accession NumberQ9NQ25
BackgroundElotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents.
• SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin., PMID:28424516
• 2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer., PMID:30347240
• CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma., PMID:23731618
• CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes., PMID:17878365
• The multifaceted role of CS1 (SLAMF7) in immunoregulation: Implications for cancer therapy and autoimmune disorders., PMID:40073958
• Hematologic Malignancies: Plasma Cell Disorders., PMID:28561703
• Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma., PMID:28356715
• 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes., PMID:11513145
• Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma., PMID:39060023
• Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma., PMID:27533882
Alternative NamesABBV-383, PR-1471272, ABBV-838, 1826819-57-1
NoteFor research use only. Not suitable for clinical or therapeutic use.
For Research Use Only. Not for Diagnostic Procedures.

Related Products:
Total 33055 records,Divided into 1653 pages,The 1 pages | First Prev Next Last
Live Chat
  • Tel:
  • WeChat ID: 15898894496
  • Add Message
  • 9:00 AM – 6:00 PM